Moderna Inc.
Moderna, Inc. Announces New $1.5 Billion Credit Facility
Summary
On November 19, 2025, Moderna, Inc. entered into a Credit and Guaranty Agreement for a $1.5 billion credit facility. The agreement includes an initial term loan of $600 million and $900 million in delayed draw term loans, contingent on achieving key regulatory milestones. The facility is secured by an all-asset collateral grant and is subject to certain financial covenants. This new credit facility provides Moderna with significant liquidity to support its operations and late-stage clinical pipeline.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement